Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer: two case reports
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Immune checkpoint inhibitor (ICI)-associated adrenal insufficiency is rare but may become a serious adverse event in patients treated with ICIs. The present case report documents two cases of adrenal insufficiency developed during chemotherapy plus tislelizumab (百泽安, Baize’an; BeiGene Ltd.) therapy in patients with advanced gastric cancer. Adrenal insufficiency developed after 6 and 13 cycles of treatment and was well controlled with hydrocortisone. The patients also developed hypothyroidism, which was managed with levothyroxine. Two patients showed a partial response, and one patient out of two achieved a near-complete response, sustaining over 11 months. Increased awareness of ICI-related adrenal insufficiency is crucial for early detection and prompt management of patients treated with ICIs.
Abstract
Immune checkpoint inhibitor (ICI)-associated adrenal insufficiency is rare but may become a serious adverse event in patients treated with ICIs. The present case report documents two cases of adrenal insufficiency developed during chemotherapy plus tislelizumab (百泽安, Baize’an; BeiGene Ltd.) therapy in patients with advanced gastric cancer. Adrenal insufficiency developed after 6 and 13 cycles of treatment and was well controlled with hydrocortisone. The patients also developed hypothyroidism, which was managed with levothyroxine. Two patients showed a partial response, and one patient out of two achieved a near-complete response, sustaining over 11 months. Increased awareness of ICI-related adrenal insufficiency is crucial for early detection and prompt management of patients treated with ICIs.
참고문헌 (14)
- Global Burden of Disease Cancer Collaboration, "Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015 : a systematic analysis for the global burden of disease study", JAMA Oncol, 3, pp.524~548 (2017)
- Jim MA, "Stomach cancer survival in the United States by race and stage(2001-2009) : findings from the CONCORD-2 study", Cancer, 123(Suppl 24), pp.4994~5013 (2017)
- Zhang T, "The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions", Cancer Immunol Immunother, 67, pp.1079~1090 (2018)
- Lee A, "Tislelizumab : first approval", Drugs, 80, pp.617~624 (2020)
- Borghaei H, "Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer", N Engl J Med, 373, pp.1627~1639 (2015)
- Barroso-Sousa R, "Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens : a systematic review and meta-analysis", JAMA Oncol, 4, pp.173~182 (2018)
- Wang DY, "Fatal toxic effects associated with immune checkpoint inhibitors : a systematic review and meta-analysis", JAMA Oncol, 4, pp.1721~1728 (2018)
- Oelkers W, "Hyponatremia and inappropriate secretion of vasopressin(antidiuretic hormone)in patients with hypopituitarism", N Engl J Med, 321, pp.492~496 (1989)
- Wolfson B, "Co-localization of corticotropin releasing factor and vasopressin mRNA in neurones after adrenalectomy", Nature, 315, pp.59~61 (1985)
- Watts AG, "Corticotropin-releasing hormone and arginine vasopressin gene transcription in the hypothalamic paraventricular nucleus of unstressed rats : daily rhythms and their interactions with corticosterone", Endocrinology, 145, pp.529~540 (2004)
- Judd J, "Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors", Oncologist, 22, pp.1232~1237 (2017)
- Horvat TZ, "Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center", J Clin Oncol, 33, pp.3193~3198 (2015)
- Hussaini S, "Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors : a systematic review and meta-analysis", Cancer Treat Rev, 92, pp.102134~ (2021)
- Brahmer JR, "Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy : American Society of Clinical Oncology clinical practice guideline", J Clin Oncol, 36, pp.1714~1768 (2018)